ECM
KLRS

Endurant Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Endurant Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,932
Closed -$1.11M – 81
2021
Q3 		$1.11M Buy
+1,932
New +$895K 0.25% 49

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Endurant Capital Management's KLRS Position: Q4 2021 in Review

Endurant Capital Management sold out of Kalaris Therapeutics (KLRS) in Q4 2021, closing a stake of 1,932 shares — an estimated $1.11M sold.

Endurant Capital Management first reported a position in KLRS in Q3 2021 and held it in 1 quarter. The position peaked at $1.11M in Q3 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q4 2021.

  • Endurant Capital Management reported no remaining Kalaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Endurant Capital Management sold 1,932 Kalaris Therapeutics shares in Q4 2021, an estimated $1.11M.
  • Endurant Capital Management first reported a position in Kalaris Therapeutics in Q3 2021 and held it in 1 quarter.
  • Endurant Capital Management's Kalaris Therapeutics position peaked at $1.11M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2021.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.